Key Insights from the HER2CLIMB Trial

Panelists discuss key data from the HER2CLIMB study, which evaluates the efficacy of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for patients with advanced HER2+ breast cancer, highlighting outcomes across patient subgroups and the clinical significance of findings related to patients with measurable baseline intracranial disease.

EP: 1.Overview of HER2 Breast Cancer

EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians

EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach

EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective

EP: 5.Tailoring Patient Education and Resources in HER2+ Breast Cancer

EP: 6.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey

EP: 7.Navigating Systemic Therapy Options in HER2+ Breast Cancer

Now Viewing

EP: 8.Key Insights from the HER2CLIMB Trial

EP: 9.Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

EP: 10.BRIDGET Trial: Strategies in Maintenance Therapy for HER2+ Breast Cancer with Brain Metastases

EP: 11.Preparing Patients for Treatment: Education, Administration and Adverse Effect Management in HER2+ Breast Cancer

EP: 12.Patient Perspectives on Managing Adverse Effects from Capecitabine, Trastuzumab, and Tucatinib

EP: 13.Comprehensive Supportive Care for Metastatic HER2+ Breast Cancer

EP: 14.Patient Perspective: Key Aspects of Supportive Care in the HER2+ Breast Cancer Journey

1. Dr Iyengar: Briefly discuss key data from the HER2CLIMB study, evaluating tucatinib in combination with trastuzumab and capcitabine capecitabine for patients with advanced HER2+ breast cancer.
   1. Please comment on the efficacy outcomes across patient subgroups.
   2. What is the clinical significance for findings in patients with advanced HER2+ breast cancer and measurable baseline intracranial disease?

Recent Videos